The investigators will be measuring vitamin D metabolites in blood samples drawn from patients undergoing cardiac surgery to determine the correlation with renal function as assessed by serum creatinine. The investigators will include 20 patients in each of the following 3 groups based on serum creatinine measured within 28-days of surgery: 1) normal kidney function (eGFR \> 60 mL/min, n=20), 2) moderate impaired kidney function, eGFR between 30 and 60 mL/min (n=20) and 3) severe kidney dysfunction eGFR \< 30 mL/min (n=20).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria
* ≥ 18 years
* Patients undergoing cardiac surgery
* Serum Creatinine measured with 28 days of surgery
Exclusion Criteria
* Exogeneous calcitriol (1,25(OH)2D3) intake
* History of parathyroidectomy
* Patients with liver or kidney cancer
* Patients with liver disease (e.g. liver failure, cirrhosis)
Primary outcome measure(s)
Determine the correlation between eGFR as determined serum creatinine and vitamin D metabolites as markers of kidney function — Up to 1 month before surgery up until POD 7 serum creatinine (sCr) and vitamin D metabolites (specifically 25(OH)D3 and 1,25(OH)2D3) will be measured in the same blood sample to determine the incidence of AKI and CKD in patients undergoing cardiac surgery
Trial sites (1)
Facility
City
Region
Status
University Health Network-Toronto General Hospital
Toronto
Ontario
More University Health Network, Toronto trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.